{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-26-000005","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.416471+00:00","generated_at":"2026-05-16T10:45:53.804581+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ANI Pharma 2025 rev ~$854-873M, Cortrophin Gel up 76% YoY; 2026 rev target $1.06-1.12B","bullets":["Full-year 2025 total net revenues expected within or above $854M-$873M guidance ( ~39% YoY growth).","Cortrophin Gel net rev $347.8M in 2025 (+76% YoY); Q4 Cortrophin Gel $111.4M (+88% YoY).","2026 guidance: total net rev $1,055M-$1,115M, Cortrophin Gel $540M-$575M, adj EBITDA $275M-$290M, adj EPS $8.83-$9.34.","Plans to expand Rare Disease sales force by ~90 in mid-2026 to target acute gouty arthritis flares.","Unrestricted cash $285M at Dec 31, 2025; ILUVIEN+YUTIQ combined rev $74.9M in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-26-000005","json":"https://secwatch.observer/filing/0001023024-26-000005.json","markdown":"https://secwatch.observer/filing/0001023024-26-000005.md","text":"https://secwatch.observer/filing/0001023024-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000005/0001023024-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000005/ani-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:45:53.804581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}